ArticleBiochemical genetics2022
CircATIC Contributes to Multiple Myeloma Progression via miR-324-5p-Dependent Regulation of HGF.
Article in Biochemical genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 6 citations in OpenAlex.
- Atomoxetine suppresses radioresistance in glioblastoma via circATIC/miR-520d-5p/Notch2-Hey1 axis.Cell communication and signaling : CCS · 2024Article
- Article
- N6-methyladenosine-modified circ_0000337 sustains bortezomib resistance in multiple myeloma by regulating DNA repair.Frontiers in cell and developmental biology · 2024Article
- Recent Progress of CircRNAs in Hematological Malignancies.International journal of medical sciences · 2024Review
- Exploring circRNA_19601 as a therapeutic target in diabetic neuropathic pain: Insights from rat and cell models.Molecular painArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circular RNA (circRNA) 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (circATIC; hsa_circ_0058058) was observed to be upregulated in multiple myeloma (MM) by former article. However, the function and exact mechanism of circATIC in MM development remain barely known. CircRNA-microRNA (miRNA)-messenger RNA (mRNA) axis was established through using bioinformatic databases (starbase, Circinteractome, and microT-CDS). Dual-luciferase reporter assay, RNA immunoprecipitation assay, and RNA-pull down assay were utilized to verify the target relationship between microRNA-324-5p (miR-324-5p) and circATIC or hepatocyte growth factor (HGF). CircATIC expression was upregulated in MM patients and cell lines. CircATIC interference notably hampered cell proliferation, migration, invasion, and glycolysis and induced cell apoptosis of MM cells. MiR-324-5p was a target of circATIC. CircATIC silencing-mediated effects in MM cells were largely overturned by the knockdown of miR-324-5p. HGF was a target of miR-324-5p, and circATIC upregulated the expression of HGF partly through sponging miR-324-5p in MM cells. MiR-324-5p suppressed the malignant behaviors of MM cells, which were largely counteracted by the overexpression of HGF in MM cells. CircATIC accelerated the proliferation, migration, invasion, and glycolysis and suppressed the apoptosis of MM cells through mediating miR-324-5p/HGF signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.